Increasing access to medical oncology consultation in older patients with stage II-IIIA non-small-cell lung cancer

Medical Oncology

Volumn 25, Issue 2, 2008, Pages 125-132

  Wang, Jue ^a   Kuo, Yong Fang ^b   Freeman, Jean ^b   Goodwin, James S ^b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

Adjuvant chemotherapy; Medical oncology consultation; Non small cell lung cancer (NSCLC); SEER Medicare database

Indexed keywords

ANTINEOPLASTIC AGENT;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CONSULTATION; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; ONCOLOGY; PRIORITY JOURNAL; CANCER REGISTRY; LUNG TUMOR; MULTIVARIATE ANALYSIS; PATHOLOGY; PATIENT REFERRAL;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MEDICAL ONCOLOGY; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; REFERRAL AND CONSULTATION; SEER PROGRAM;

EID: 48049084809     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-007-9003-5     Document Type: Article

References (25)

1. A Jemal R Siegel E Ward T Murray J Xu MJ Thun 2007 Cancer statistics, 2007 CA Cancer J Clin 57 1 43 66
2. DM Parkin F Bray J Ferlay P Pisani 2005 Global cancer statistics, 2002 CA Cancer J Clin 55 2 74 108
3. Shields TW. Surgical treatment of non-small cell bronchial carcinoma. In: Shields TW, (ed). General thoracic surgery. 3rd ed. Philadelphia: Williams and Wilkins. 1994;1169.
4. R Arriagada B Bergman A Dunant T Le Chevalier JP Pignon J Vansteenkiste 2004 International adjuvant lung cancer trial collaborative group N Engl J Med 350 4 351 60
5. TL Winton R Livingston D Johnson 2005 Vinorelbine and cisplatin vs. observation in resected non-small-cell lung cancer N Engl J Med 352 2589 97
6. GM Strauss JE Herndon MA Maddaus 2006 Adjuvant chemotherapy in stage IB non-small cell lung cancer (SCLC): update of Cancer and Leukemia Group B (CALGB) Protocol 9633 [abstract] Proc Am Soc Clin Oncol 24 365
7. J Douillard R Rosell M Delena 2005 ANITA: phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I-III) non-small-cell lung cancer (NSCLC) patients (pts); final results after 70-month median follow-up [abstract] Proc Am Soc Clin Oncol 24 619
8. JL Warren CN Klabunde D Schrag 2002 Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population Med Care 40 8 suppl IV-3 18
9. SEER-Medicare: Calculation of Comorbidity Weights. Available at http://healthservices.cancer.gov/seermedicare/program/comorbidity.html
10. LM Baldwin W Adamache CN Klabunde 2002 Linking physician characteristics and Medicare claims data: issues in data availability, quality, and measurement Med Care 40 8 suppl IV-82 95
11. JS Goodwin JL Freeman JD Mahnken DH Freeman AB Nattinger 2002 Geographic variations in breast cancer survival among older women: implications for quality of breast cancer care J Gerontol A Biol Sci Med Sci 57 6 M401 6
12. T Christmas M Findlay 2004 Lung cancer treatment in New Zealand: physician's attitudes N Z Med J 117 1196 U931
13. A Motohiro N Hirota H Komatsu N Yanai 1994 Japanese doctors' preferred treatment choices for their hypothetical non-small cell lung cancer: how they would wish to be treated Lung Cancer 11 1-2 43 50
14. Central European Cooperative Oncology Group (CECOG) 2002 Advisory Committee on Collaboration with Industry in Medical Education of the European School of Oncology (ESO); Vienna Medical Association. Consensus on medical treatment of non-small cell lung cancer Lung Cancer 38 Suppl 3 S3 7
15. A Spira DS Ettinger 2004 Multidisciplinary management of lung cancer N Engl J Med 350 4 379 92
16. BJ Kennedy 1999 Origin and evolution of medical oncology Lancet 354 Suppl SIV41
17. BJ Kennedy 1997 Medical oncology as a discipline Oncology 54 6 459 62
18. DC Betticher 2005 Adjuvant, neoadjuvant chemotherapy in NSCLC: a paradigm shift Lung Cancer 50 Suppl 2 S9 16
19. MJ Palmer B O'Sullivan R Steele WJ Mackillop 1990 Controversies in the management of non-small cell lung cancer: the results of an expert surrogate study Radiother Oncol 19 1 17 28
20. CC Earle PJ Neumann RD Gelber MC Weinstein JC Weeks 2002 Impact of referral patterns on the use of chemotherapy for lung cancer J Clin Oncol 20 7 1786 92
21. ER Greenberg B Dain D Freeman J Yates R Korson 1988 Referral of lung cancer patients to university hospital cancer centers A population-based study in two rural states Cancer 62 8 1647 52
22. ER Greenberg CG Chute T Stukel JA Baron DH Freeman J Yates R Korson 1988 Social and economic factors in the choice of lung cancer treatment. A population-based study in two rural states N Engl J Med 318 10 612 7
23. R Luo SH Giordano JL Freeman D Zhang JS Goodwin 2006 Referral to medical oncology: a crucial step in the treatment of older patients with stage III colon cancer Oncologist 11 9 1025 33
24. D Polsky KA Armstrong TC Randall RN Ross O Even-Shoshan PR Rosenbaum JH Silber 2006 Variation in chemotherapy utilization in ovarian cancer: the relative contribution of geography Health Serv Res 41 6 2201 18
25. RR Jennens GG Giles RM Fox 2006 Increasing underrepresentation of elderly patients with advanced colorectal or non-small-cell lung cancer in chemotherapy trials Intern Med J 36 4 216 20